Product Description
Ademetionine (S-adenosylmethionine; SAMe) is a ubiquitous metabolite present in all cells and biological fluids, and serves as a methyl donor in a multitude of different methylation reactions involving proteins, phospholipids, catecholamines and DNA. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/15989609/)
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Australia | Brazil | Bulgaria | China | Colombia | Czech | Ecuador | India | Italy | Korea | Lithuania | Malaysia | Mexico | Peru | Philippines | Russia | Slovenia | Ukraine | United Arab Emirates | United Kingdom | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Abbott Laboratories
Company Location: ABBOTT PARK IL 60064-3500
Company CEO: Robert B. Ford
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, China, Hong Kong, Italy, Korea, New Zealand, Thailand
Active Clinical Trial Count: 4
Highest Development Phases
Phase 3: Depressive Disorder, Major
Phase 2: Hepatitis B, Chronic|Intestinal Diseases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| MYL-1603N-3001 | P3 |
Unknown Status |
Depressive Disorder, Major |
2027-01-31 |
|
| 2017-003073-33 | P3 |
Active, not recruiting |
Depressive Disorder, Major |
2026-11-08 |
|
| MYL-1603N-3002 | P3 |
Unknown Status |
Depressive Disorder, Major |
2025-06-19 |
|
| 2006-7041-83/hah | P2 |
Not yet recruiting |
Intestinal Diseases|Hepatitis B, Chronic |
2020-03-31 |